[1]白 雪,邓 琦.血液系统肿瘤的细胞治疗研究进展[J].医学信息,2018,31(10):41-43,47.[doi:10.3969/j.issn.1006-1959.2018.10.013]
　BAI Xue,DENG Qi.Advances in Cell Therapy for Blood System Tumor[J].Journal of Medical Information,2018,31(10):41-43,47.[doi:10.3969/j.issn.1006-1959.2018.10.013]
点击复制

血液系统肿瘤的细胞治疗研究进展()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
31卷
期数:
2018年10期
页码:
41-43,47
栏目:
综述
出版日期:
2018-05-15

文章信息/Info

Title:
Advances in Cell Therapy for Blood System Tumor
文章编号:
1006-1959（2018）10-0041-04
作者:
白 雪; 邓 琦
天津市第一中心医院血液科，天津 300192
Author(s):
BAI Xue; DENG Qi
Department of Hematology,Tianjin First Central Hospital,Tianjin 300192,China
关键词:
血液系统; 肿瘤; 细胞治疗
Keywords:
Key words：Blood system; Tumor; Cell therapy
分类号:
R733
DOI:
10.3969/j.issn.1006-1959.2018.10.013
文献标志码:
A
摘要:
随着经济发展与环境改变，肿瘤发病率增高，威胁着人们的健康。血液系统是机体的重要构成部分，该系统的肿瘤发生率有逐年上升的趋势。传统的药物治疗、手术治疗等方式为挽救患者的生命、提高其生活质量、提供了更好的选择。但是，该疾病存在复发率较高等现象，亟待开发更有效的治疗方法。细胞治疗为血液肿瘤患者提供了副作用更低的治疗手段，延长患者的生存期，提高了生活质量。基于细胞的治疗策略，可提高对血液肿瘤的治疗效果。本文对血液系统肿瘤的细胞治疗研究进行综述，以期为该疾病的临床治疗提供参考。
Abstract:
Abstract：With the economic development and environmental changes,the incidence of cancer increases,threatening people's health. The blood system is an important part of the body.The incidence of tumors in this system has increased year by year.Traditional medical treatment,surgical treatment and other methods provide better options for saving the lives of patients and improving their quality of life.However,there is a high rate of recurrence of this disease,and it is urgent to develop more effective treatments.Cellular therapy provides patients with blood tumor with less side-effects,prolongs their survival and improves their quality of life.Cell-based therapeutic strategies can increase the therapeutic effect on blood tumors.This article reviews the research on cell therapy of blood system tumors in order to provide reference for the clinical treatment of the disease.

参考文献/References:

[1]Couzin-Frankel J.Breakthrough of the year 2013.Cancer immunotherapy[J].Science,2013,342(6165):1432.
[2]Vacchelli E,Eggermont A,Fridman W H,et al.Trial Watch: Adoptive cell transfer for anticancer immunotherapy[J].Oncoimmunology,2013,2(5):24238.
[3]张巍,景红梅,王继军,等.细胞免疫疗法对血液系统恶性肿瘤治疗作用的研究进展[J].中国实验血液学杂志,2017,25(3):941-946.
[4]王艳,席洁琳,黄晓兵,等.细胞因子诱导的杀伤细胞治疗血液系统恶性肿瘤研究进展[J].实用医院临床杂志,2013,10(02):157-159.
[5]张超然,关心,杨同华.细胞因子诱导的杀伤细胞联合其他方案治疗血液肿瘤研究进展[J].实用医学杂志,2016,32(2):324-326.
[6]杨红旗,李红俊,沙薇薇,等.自体CIK细胞输注治疗高龄血液肿瘤21例临床护理[J].齐鲁护理杂志,2017,23(21):72-74.
[7]成红.DC与CIK细胞免疫治疗在血液肿瘤中的临床效果观察[J].哈尔滨医药,2014,34(5):292-292.
[8]高宏伟,郭文家, 哈小琴,等.嵌合抗原受体T细胞技术在血液系统肿瘤治疗中的应用[J].检验医学与临床,2016,13(24):3567-3570.
[9]桑秀莉,史策,周晋.CAR-T细胞治疗在血液系统恶性肿瘤中的研究进展[J].实用肿瘤学杂志,2016,30(05):473-476.
[10]何爱丽,王夏曼.CAR-T细胞治疗在血液肿瘤中的研究进展与问题[J].西部医学,2016, 28(10):1333-1338.
[11]夏莉,王月英.嵌合抗原受体T细胞疗法及其在血液肿瘤免疫治疗中的应用[J].上海交通大学学报(医学版),2017,37(6):822-829.
[12]Jensen MC,Popplewell L,Cooper LJ,et al.Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20 CD19-specific chimeric antigen receptor redirected T cells in humans[J].Biol Blood Marrow Transplant,2010,16(9):1245-1256.
[13]Pegram HJ,Lee JC,Hayman EG,et al.Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning[J].Blood,2012,119(18):4133.
[14]侯萍,李剑平.表达嵌合抗原受体修饰T细胞治疗血液系统恶性肿瘤的最新研究与进展[J].中国组织工程研究,2017,21(21):3438-3444.
[15]克晓燕.嵌合抗原受体-T细胞免疫治疗在血液系统恶性肿瘤中的应用进展[J].中国全科医学,2016,19(12):1361-1366.
[16]李军,陈雄波,董坚.CAR-T细胞治疗在血液肿瘤中的临床研究[J].生物产业技术,2017,11(05):27-32.
[17]Kochenderfer JN,Dudley ME,Kassim SH,et al.Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor[J].Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology,2015,33(6):540-549.
[18]Grupp SA,Kalos M,Barrett D,et al.Chimeric antigen receptor-modified T cells for acute lymphoid leukemia[J].N Engl J Med,2013,368(16):1509.
[19]Porter DL,Hwang WT,Frey NV,et al.Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia[J].Sci Transl Med,2015,7(303):303ra139.
[20]刘凯,王多明,王若峥.细胞毒性T淋巴细胞免疫与肿瘤相关研究进展[J].新疆医科大学学报,2017,40(7):871-875.
[21]Geiger TL,Sun JC.Development and maturation of natural killer cells[J].Curr Opin Immunol,2016,39(6):82.
[22]辛盼盼,杨志刚.血液肿瘤逃逸NK细胞免疫监控机制及其治疗的研究进展[J].广东医学院学报,2013,31(02):213-216.
[23]王雯欣,黄娟娟,王振坤,等.NK 细胞治疗血液系统恶性肿瘤的研究进展[J].检验医学与临床,2016,13(9):1286-1288.
[24]Konjevi G,Vuleti A,Mirjai MK.Natural killer cell receptors: alterations and therapeutic targeting in malignancies[J].Immunol Res,2016,64(1):25-35.
[25]Stern M,Passweg JR,Meyermonard S,et al.Pre-emptive immunotherapy with purified natural killer cells after haploidentical SCT:a prospective phase Ⅱ study in two centers[J].Bone Marrow Transplantation,2013,48(3):433-438.
[26]Rubnitz JE,Inaba H,Kang G,et al.Natural killer cell therapy in children with relapsed leukemia[J].Pediatri Blood Cancer,2015,62(8):1468-1472.
[27]Boissel L,Betancurboissel M,Lu W,et al.Retargeting NK-92 cells by means of CD19-and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity[J].Oncoimmunology,2013,2(10):26527.
[28]周峰,韩文敏,贾祝霞,等.扩增脐血来源NK细胞增强其抗血液肿瘤细胞作用的研究[J].中华血液学杂志,2013,34(11):952-956.
[29]罗荣牡,达万明,张晓妹,等.亲缘单倍体造血干细胞移植治疗22例儿童高危血液肿瘤的安全性及疗效分析[J].中国小儿血液与肿瘤杂志,2013,18(6):255-258.
[30]韦惠琴,钟卫一,王锦香.混合外周造血干细胞移植治疗血液肿瘤4例临床研究[J].临床荟萃,2013, 28(6):675-676.

相似文献/References:

[1]杨森果,毛大华,杨海松,等.E-cadherin与肿瘤侵袭、转移相关性研究进展[J].医学信息,2018,31(03):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
　YANG Sen-guo,MAO Da-hua,YANG Hai-song,et al.Research Progress of the Correlation between E-cadherin and Tumor Invasion and Metastasis[J].Journal of Medical Information,2018,31(10):3.[doi:10.3969/j.issn.1006-1959.2018.04.002]
[2]江立基,李先明.碳酸酐酶Ⅸ在肿瘤中的研究进展[J].医学信息,2018,31(03):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
　JIANG Li-ji,LI Xian-ming.Research Progress of Carbonic Anhydrase IX in Cancer[J].Journal of Medical Information,2018,31(10):7.[doi:10.3969/j.issn.1006-1959.2018.03.003]
[3]靳雪芹,邓正聪.代谢综合征与肿瘤关系的研究进展[J].医学信息,2018,31(05):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
　JIN Xue-qin,DENG Zheng-cong.Research Progress on the Relationship between Metabolic Syndrome and Tumor[J].Journal of Medical Information,2018,31(10):35.[doi:10.3969/j.issn.1006-1959.2018.05.014]
[4]李 轩,王子为,赵靖萱,等.肿瘤预后预测领域机器学习应用的文献计量与热点可视化分析[J].医学信息,2022,35(09):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
　LI Xuan,WANG Zi-wei,ZHAO Jing-xuan,et al.Visualization Analysis on Bibliometrics and Hot Spots of Machine Learning Applications in the Field of Tumor Prognosis Prediction[J].Journal of Medical Information,2022,35(10):90.[doi:10.3969/j.issn.1006-1959.2022.09.023]
[5]王 静,刘 梅,焦菊凤.知-信-行健康教育模式对PICC置管肿瘤 患者自我护理能力的影响[J].医学信息,2018,31(11):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
　WANG Jing,LIU Mei,JIAO Ju-feng.Effect of Knowledge-belief-behavioral Health Education Model on the Self-care Ability of Patients with Cancer in PICC Catheterization[J].Journal of Medical Information,2018,31(10):170.[doi:10.3969/j.issn.1006-1959.2018.11.056]
[6]史红娟,李群锋,赵 华,等.舒林酸抗肿瘤作用的研究进展[J].医学信息,2018,31(12):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
　SHI Hong-juan,LI Qun-feng,ZHAO Hua,et al.Advances in Research on Anti-tumor Effect of Sulindac[J].Journal of Medical Information,2018,31(10):35.[doi:10.3969/j.issn.1006-1959.2018.12.012]
[7]庞小坤,韩 梅,江心灿,等.当归补血汤治疗肿瘤化疗不良反应随机对照临床试验的Meta分析[J].医学信息,2019,32(02):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
　Pang Xiao-kun,Han Mei,Jiang Xin-can,et al.Meta-analysis of a Randomized Controlled Clinical Trial of Angelica Buxue Decoction in the Treatment of Adverse Reactions to Chemotherapy[J].Journal of Medical Information,2019,32(10):69.[doi:10.3969/j.issn.1006-1959.2019.02.021]
[8]张 慧,胡广越,殷 红.菌群干预与免疫治疗的研究进展[J].医学信息,2022,35(11):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
　ZHAHG Hui,HU Guang-yue,YIN Hong.Research Progress in Microbial Intervention and Immunotherapy[J].Journal of Medical Information,2022,35(10):54.[doi:10.3969/j.issn.1006-1959.2022.11.016]
[9]郑文灿,法艳梅,吕亚青,等.苦参碱抗肿瘤机制的分子生物学研究进展[J].医学信息,2018,31(19):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
　ZHENG Wen-can,FA Yan-mei,LV Ya-qing,et al.Advances in Molecular Biology of Matrine Antitumor Mechanism[J].Journal of Medical Information,2018,31(10):51.[doi:10.3969/j.issn.1006-1959.2018.19.017]
[10]缪继东.盐酸吗啡缓释片联合低剂量阿米替林治疗中重度癌性骨痛的疗效观察[J].医学信息,2018,31(21):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]
　MIAO Ji-dong.Effects of Morphine Hydrochloride Sustained-release Tablets Combined with Low Dose Amitriptyline in the Treatment of Moderate and Severe Cancer Bone Pain[J].Journal of Medical Information,2018,31(10):147.[doi:10.3969/j.issn.1006-1959.2018.21.042]

更新日期/Last Update: 2018-05-15